home > news > detailed info

Rare and orphan disease expert Terebellum launches market access guide


Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring rare disease products to market.

The market access guide is being launched to mark Rare Disease Day (Tuesday 28th February) when it will be available to download from the Terebellum website.

Terebellum – which provides innovative, cost-saving business consulting solutions for pharmaceutical manufacturers and healthcare organisations – will share tips on how industry stakeholders can create an effective market access strategy, giving their treatment the best chance of success in a competitive sector.

Features will include why a market access strategy is important and how to develop one effectively, how to build product value, as well as insight into best practices for identifying population size and determining pricing. Readers can also learn which external partners to approach and what specialist knowledge they can acquire to bolster their own teams.

Craig Caceci, Terebellum’s managing director states: “Bringing any product to market, particularly those used to treat rare and orphan diseases is a challenge enough. But given low patient prevalence, lack of understanding about these diseases and tight budgets, there’s no guarantee your product - however needed it is - will make it to market.

“We understand that companies are up against treatments for a whole range of diseases, all competing for the same budget or funding. However our new guide explains steps you can take to give yourself the best chance - especially when having a patient for the drug doesn’t necessarily guarantee that your product will enter the market and be paid for.”

Terebellum is the Ireland and UK-based subsidiary of global specialty pharmacy and healthcare services provider, AscellaHealth, dedicated to advancing life sciences throughout Europe.

Its consultancy services include strategic guidance in the pre-commercialisation stage plus administrative and financial services, supply chain logistics and group purchasing services. Terebellum has recently launched its monthly Specialty Pharmaceutical Pulse™ insights bulletin in the UK.

It includes clinical content and updates on drug launches, the latest industry information on specialty pharmacy and treatment for rare diseases, as well as patient advocacy efforts.
Print this page
Send to a friend
News and Press Releases

FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma

Basel, 10 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favour of Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The ODAC provides the FDA with independent opinions and recommendations from outside medical experts though the recommendations are not binding. The FDA is expected to make a final decision on its review of the supplemental Biologics License Application (sBLA) for Polivy in this indication by 2 April 2023.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement